XML 47 R28.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Acquisitions and Divestitures | 12 Months Ended
--- | ---
Dec. 31, 2024
Business Combinations [Abstract] |
Acquisitions and Divestitures | Acquisitions and divestitures Acquisition of DaVita Care Pte. Ltd. Effective November 1, 2024, the Company acquired control of DaVita Care Pte. Ltd. (DVC), previously referred to as the Company's APAC joint venture, through a change in control rights for no cash consideration. See Note 8 for more information. In connection with this acquisition, the Company recognized a non-cash gain of $59,067 on its previously held equity interests in the acquiree and realized a related foreign currency gain of $15,252 from foreign currency translation adjustments on this investment which were previously classified in accumulated other comprehensive loss. The Company estimated the fair value of its previously held equity interests of $114,744 using appraisals developed with an independent third party valuation firm. The following table summarizes the assets acquired and liabilities assumed in this transaction and recognized at the acquisition date at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in this transaction:
| Year ended December 31, 2024
Cash | $ | 34,818 |
Other current assets | $ | 44,810 |
Property and equipment | 22,651 |
Other long-term assets | 37,682 |
Indefinite-lived licenses | 15,114 |
Goodwill | 127,207 |
Liabilities assumed | (54,708) |
Noncontrolling interests assumed | (112,830) |
| $ | 114,744 |
Other international and routine acquisitions During 2024, 2023 and 2022, the Company acquired other dialysis and related businesses for consideration paid in cash. As part of these other international and routine transactions in 2024, the Company acquired a controlling interest in a previously nonconsolidated U.S. dialysis partnership for which it recognized a non-cash gain of $35,147 on its prior investment upon consolidation. The Company estimated the fair value of its previously held equity interest in this business using appraisals developed with independent third party valuation firms. Aggregate consideration – DVC and all other acquisitions Aggregate consideration for both the DaVita Care Pte. Ltd. acquisition and all other international and routine acquisitions described above has been as follows:
| Year ended December 31,
| 2024 |  | 2023 |  | 2022
Cash paid | $ | 329,187 |  |  | $ | 27,648 |  |  | $ | 59,271 |
Contingent purchase price and liabilities assumed | 50,384 |  |  | 19,801 |  |  | 19,337 |
Fair value of previously held equity interests | 182,270 |  |  | — |  |  | — |
Aggregate consideration | $ | 561,841 |  |  | $ | 47,449 |  |  | $ | 78,608 |
Number of dialysis centers acquired — U.S. | 12 |  | — |  | 5
Number of dialysis centers acquired — International | 198 |  | 12 |  | 11
Purchase price allocations — DVC and all other acquisitions The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company’s consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. For several of the 2024 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of contingent earn-outs, intangibles, fixed assets, leases and certain working capital items relating to several of these acquisitions are pending final quantification. The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:
| Year ended December 31,
| 2024 |  | 2023 |  | 2022
Cash | $ | 83,119 |  |  | $ | 1,254 |  |  | $ | 1,963 |
Other current assets | 249,738 |  |  | 6,128 |  |  | 6,389 |
Property and equipment | 94,951 |  |  | 4,130 |  |  | 7,481 |
Right-of-use lease assets and other long-term assets | 97,591 |  |  | 785 |  |  | 1,066 |
Indefinite-lived licenses | 22,725 |  |  | 15,789 |  |  | 19,610 |
Goodwill | 349,069 |  |  | 25,723 |  |  | 49,047 |
Liabilities assumed | (201,704) |  |  | (6,179) |  |  | (6,081) |
Noncontrolling interests assumed | (133,648) |  |  | (181) |  |  | (867) |
| $ | 561,841 |  |  | $ | 47,449 |  |  | $ | 78,608 |
The amount of goodwill related to these acquisitions recognized or adjusted in 2024, 2023 and 2022 that is deductible for local tax purposes was $54,810, $17,836 and $49,047, respectively. Pro forma financial information (unaudited) The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions in 2024 and 2023 had been consummated as of the beginning of 2023, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.
| Year ended December 31,
| 2024 |  | 2023
| (unaudited)
Pro forma total revenues | $ | 13,073,083 |  |  | $ | 12,625,223 |
Pro forma net income attributable to DaVita Inc. | $ | 952,836 |  |  | $ | 732,265 |
Pro forma basic net income per share attributable to DaVita Inc. | $ | 11.21 |  |  | $ | 8.07 |
Pro forma diluted net income per share attributable to DaVita Inc. | $ | 10.92 |  |  | $ | 7.86 |

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContent + Details
Name: | us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration